299 related articles for article (PubMed ID: 31876436)
41. Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation.
Matsuda Y; Malinao MC; Robles V; Song J; Yamada K; Mendelsohn BA
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Mar; 1140():121981. PubMed ID: 32036254
[TBL] [Abstract][Full Text] [Related]
42. Current methods for the synthesis of homogeneous antibody-drug conjugates.
Sochaj AM; Świderska KW; Otlewski J
Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
[TBL] [Abstract][Full Text] [Related]
43. Site-Specific Conjugation of Thiol-Reactive Cytotoxic Agents to Nonnative Cysteines of Engineered Monoclonal Antibodies.
Dickgiesser S; Kellner R; Kolmar H; Rasche N
Methods Mol Biol; 2019; 2033():1-14. PubMed ID: 31332743
[TBL] [Abstract][Full Text] [Related]
44. Site-selective antibody-lipid conjugates for surface functionalization of red blood cells and targeted drug delivery.
Li B; Yuan D; Chen H; Wang X; Liang Y; Wong CTT; Xia J
J Control Release; 2024 Jun; 370():302-309. PubMed ID: 38663752
[TBL] [Abstract][Full Text] [Related]
45. Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.
Kolodych S; Michel C; Delacroix S; Koniev O; Ehkirch A; Eberova J; Cianférani S; Renoux B; Krezel W; Poinot P; Muller CD; Papot S; Wagner A
Eur J Med Chem; 2017 Dec; 142():376-382. PubMed ID: 28818506
[TBL] [Abstract][Full Text] [Related]
46. A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy.
Maruani A; Smith ME; Miranda E; Chester KA; Chudasama V; Caddick S
Nat Commun; 2015 Mar; 6():6645. PubMed ID: 25824906
[TBL] [Abstract][Full Text] [Related]
47. Distinctive Low-Resolution Structural Features of Dimers of Antibody-Drug Conjugates and Parent Antibody Determined by Small-Angle X-ray Scattering.
Law-Hine D; Rudiuk S; Bonestebe A; Ienco R; Huille S; Tribet C
Mol Pharm; 2019 Dec; 16(12):4902-4912. PubMed ID: 31618040
[TBL] [Abstract][Full Text] [Related]
48. Design, Synthesis, and in vitro Evaluation of Multivalent Drug Linkers for High-Drug-Load Antibody-Drug Conjugates.
Chen B; Gianolio DA; Stefano JE; Manning CM; Gregory RC; Busch MM; Brondyk WH; Miller RJ; Dhal PK
ChemMedChem; 2018 Apr; 13(8):790-794. PubMed ID: 29517131
[TBL] [Abstract][Full Text] [Related]
49. Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry.
Sang H; Lu G; Liu Y; Hu Q; Xing W; Cui D; Zhou F; Zhang J; Hao H; Wang G; Ye H
Anal Chim Acta; 2017 Feb; 955():67-78. PubMed ID: 28088282
[TBL] [Abstract][Full Text] [Related]
50. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes.
Drake PM; Albers AE; Baker J; Banas S; Barfield RM; Bhat AS; de Hart GW; Garofalo AW; Holder P; Jones LC; Kudirka R; McFarland J; Zmolek W; Rabuka D
Bioconjug Chem; 2014 Jul; 25(7):1331-41. PubMed ID: 24924618
[TBL] [Abstract][Full Text] [Related]
51. Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.
Li X; Patterson JT; Sarkar M; Pedzisa L; Kodadek T; Roush WR; Rader C
Bioconjug Chem; 2015 Nov; 26(11):2243-8. PubMed ID: 26161903
[TBL] [Abstract][Full Text] [Related]
52. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
Elgersma RC; Coumans RG; Huijbregts T; Menge WM; Joosten JA; Spijker HJ; de Groot FM; van der Lee MM; Ubink R; van den Dobbelsteen DJ; Egging DF; Dokter WH; Verheijden GF; Lemmens JM; Timmers CM; Beusker PH
Mol Pharm; 2015 Jun; 12(6):1813-35. PubMed ID: 25635711
[TBL] [Abstract][Full Text] [Related]
53. Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs).
Hoffmann RM; Mele S; Cheung A; Larcombe-Young D; Bucaite G; Sachouli E; Zlatareva I; Morad HOJ; Marlow R; McDonnell JM; Figini M; Lacy KE; Tutt AJN; Spicer JF; Thurston DE; Karagiannis SN; Crescioli S
Sci Rep; 2020 Jun; 10(1):8869. PubMed ID: 32483228
[TBL] [Abstract][Full Text] [Related]
54. Proximity-Induced Site-Specific Antibody Conjugation.
Yu C; Tang J; Loredo A; Chen Y; Jung SY; Jain A; Gordon A; Xiao H
Bioconjug Chem; 2018 Nov; 29(11):3522-3526. PubMed ID: 30372039
[TBL] [Abstract][Full Text] [Related]
55. Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species.
Glover ZK; Wecksler A; Aryal B; Mehta S; Pegues M; Chan W; Lehtimaki M; Luo A; Sreedhara A; Rao VA
MAbs; 2022; 14(1):2122957. PubMed ID: 36151884
[TBL] [Abstract][Full Text] [Related]
56. MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding
Avilés P; Domínguez JM; Guillén MJ; Muñoz-Alonso MJ; Mateo C; Rodriguez-Acebes R; Molina-Guijarro JM; Francesch A; Martínez-Leal JF; Munt S; Galmarini CM; Cuevas C
Mol Cancer Ther; 2018 Apr; 17(4):786-794. PubMed ID: 29440297
[TBL] [Abstract][Full Text] [Related]
57. Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar.
Zhu Z; Ramakrishnan B; Li J; Wang Y; Feng Y; Prabakaran P; Colantonio S; Dyba MA; Qasba PK; Dimitrov DS
MAbs; 2014; 6(5):1190-200. PubMed ID: 25517304
[TBL] [Abstract][Full Text] [Related]
58. HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
Pegram MD; Miles D; Tsui CK; Zong Y
Clin Cancer Res; 2020 Feb; 26(4):775-786. PubMed ID: 31582515
[TBL] [Abstract][Full Text] [Related]
59. Quantitative collision-induced unfolding differentiates model antibody-drug conjugates.
Tian Y; Lippens JL; Netirojjanakul C; Campuzano IDG; Ruotolo BT
Protein Sci; 2019 Mar; 28(3):598-608. PubMed ID: 30499138
[TBL] [Abstract][Full Text] [Related]
60. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
